Alethia Bio Raises VC

Alethia Biotherapeutics, a Montreal-based developer of monoclonal antibodies for the treatment and prevention of severe bone loss, ovarian cancer, and metastatic breast cancer, has raised C$2.4 million in VC funding from BDC Venture Capital and GO Capital Fund. Read more